My Treatment Approach: Optimizing Care for Relapsed / Refractory Multiple Myeloma: Translating Evidence to Clinical Practice - Episode 5
Overview of CAR T-cell Therapy Options in R/R MM
The experts examine the available CAR T-cell therapy options for relapsed/refractory multiple myeloma.
Video content above is prompted by the following:
- What current CAR T- cell therapy options are there for r/r MM? [EX1]
- Resource Link: CARVYKTI (cilta-cel) HCP website
- Reource Link: ABECMA (ide-cel) HCP website
- What are some challenges with CAR T-cell therapy in r/r MM that you’ve experienced in your clinical practice? What are some potential resources and/or strategies to help support logistical challenges or early referral?
- What is the role of bridging therapy prior to CAR T-cell therapy?
- How do you define “bridging therapy”?
- What is the potential role of Selinexor as bridging therapy, and how have you incoporated it in your practice?
Related Content:
